A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Aspirin; Clopidogrel; Niacin; Ticlopidine

Criteria

Inclusion Criteria:

• Participant has primary hypercholesterolemia or mixed dyslipidemia (high cholesterol)

• Participant is a non-smoker

Exclusion Criteria:

• Participant has a history of chronic seizures

• Participant has a history of cancer

• Participant has a history of stomach or intestinal ulcers or any history of GI bleeding

• Participant has had major surgery, donated blood or participated in another investigational study in the past 4 weeks